In a randomized, parallel-group phase 3 equivalence study of patients with HER2-positive metastatic BC, Rugo et al [6] demonstrated equivalent efficacy and similar safety profiles between the trastuzumab biosimilar Ogivri (MYL-1401O) and trastuzumab (Herceptin) [6]. This evidence concerns the gene ERBB2 and breast cancer.